{
    "clinical_study": {
        "@rank": "114483", 
        "acronym": "SAFIR02_Lung", 
        "arm_group": [
            {
                "arm_group_label": "targeted agent", 
                "arm_group_type": "Experimental", 
                "description": "Arm A/ targeted arm: targeted maintenance from a list of 6 targeted drugs guided by the genomic analysis, AZD2014\ttablet\tper os \t50 mg bd, continuous dosing, AZD4547\ttablet\tper os \t80 mg bd, 2 weeks on/1 week off, AZD5363\tcapsule\tper os \t480 mg bd, 4 days on/3 days off, AZD8931\ttablet\tper os \t40 mg bd, continuous dosing, selumetinib\tcapsule\tper os\t75 mg bd, continuous dosing, vandetanib\ttablet\tper os\t300 mg od, continuous dosing,"
            }, 
            {
                "arm_group_label": "Standard maintenance therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Arm B / standard arm pemetrexed Intra venous\t500 mg/m2, every 3 weeks, erlotinib\ttablets\tper os\t150 mg od, continuous dosing"
            }
        ], 
        "brief_summary": {
            "textblock": "Open label multicentric randomized phase II trial, using high throughput genome analysis as\n      a therapeutic decision tool, aimed at comparing a targeted treatment administered according\n      to the identified molecular anomalies of the tumor with a standard treatment (pemetrexed in\n      Non squamous disease and erlotinib in squamous disease)"
        }, 
        "brief_title": "Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer Metastatic", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Screening phase:\n\n        Inclusion Criteria:\n\n          -  histologically proven NSCLC\n\n          -  Metastatic relapse or stage IV at diagnosis, or stage IIIb not amenable to surgery or\n             radiotherapy.\n\n          -  No EGFR-activating mutation or ALK translocation.\n\n          -  primary tumor or metastases that can be biopsied, excluding bone.\n\n          -  Age > 18 years\n\n          -  WHO Performance Status 0/1\n\n          -  Chemo-na\u00efve patients eligible to a first line platinum-based chemotherapy\n\n          -  No tumor progression observed with the current line of treatment\n\n          -  measurable target lesion or evaluable diseases RECIST\n\n        Exclusion criteria\n\n          -  Spinal cord compression and/or symptomatic or progressive brain metastases\n\n          -  Abnormal coagulation contraindicating biopsy\n\n          -  Inability to swallow\n\n          -  Major problem with intestinal absorption\n\n          -  Any clinically important abnormalities in rhythm, conduction or morphology of resting\n             ECG\n\n          -  Any factors increasing the risk of QTc prolongation or arrhythmic events\n\n          -  Experience of any of the following in the preceding 12 months: coronary artery bypass\n             graft, angioplasty, vascular stent, myocardial infarction, past or current\n             uncontrolled angina pectoris, congestive heart failure NYHA Grade \u22652, torsades de\n             pointes, current uncontrolled hypertension, cardiomyopathy\n\n          -  Past medical history of interstitial lung disease, drug-induced interstitial disease,\n             radiation pneumonitis which requires steroid treatment or any evidence of clinically\n             interstitial lung disease\n\n          -  Previous or current malignancies of other histologies within the last 5 years,\n\n          -  Evidence of severe or uncontrolled systemic disease (active bleeding diatheses, or\n             active Hepatitis B, C and HIV)\n\n          -  Diagnosis of diabetes mellitus type I or II\n\n          -  diagnosis of acne rosacea, severe psoriasis and severe atopic eczema\n\n          -  Prior exposure to anthracyclines or mitoxantrone with cumulative exposure in excess\n             of 360 mg/m\u00b2 for doxorubicin, 720 mg/m\u00b2 for epirubicin, or 72 mg/m\u00b2 for mitoxantrone\n\n          -  History of retinal degenerative disease, eye injury or corneal surgery in the\n             previous 3 months, past history of central serous retinopathy or retinal vein\n             occlusion, intraocular pressure >21 mmHg, or uncontrolled glaucoma.\n\n          -  History of heamorrhagic or thrombotic stroke, TIA or other CNS bleeds\n\n          -  Renal disease including glomerulonephritis, nephritic syndrome, Fanconi syndrome,\n             renal tubular acidosis\n\n          -  Patients using drugs that are known potent inhibitors or potent inducers or\n             substrates of cytochrome P450\n\n        Randomized phase:\n\n        Inclusion criteria\n\n          -  Patients who received 4 cycles of an induction platinum-based chemotherapy and who\n             have a SD or a PR at randomization\n\n          -  presenting at least one genomic alteration from the predefined list\n\n          -  Age > 25 years for patients planned to receive AZD4547\n\n          -  28-day washout period from chemo prior to randomization and grade \u22641 residual\n             toxicities,\n\n        Exclusion criteria\n\n          -  Life expectancy < 3 months.\n\n          -  Disease progression occuring at any time during chemotherapy and before randomization\n             or toxicity that led to the discontinuation of the platinium based chemotherapy\n             before 4 full cycles have been delivered\n\n          -  Less than 28 days from radiotherapy, less than 2 weeks from palliative radiation\n\n          -  Patients previously treated with a targeted agent in the same class as agents tested\n             in this study\n\n          -  Toxicities of grade \u22652 from any previous anti-cancer therapy\n\n          -  Altered haematopoietic or organ function,\n\n          -  Mean resting corrected QT interval (QTc)>480msec (or QTcF >450 msec) obtained from 3\n             consecutive ECGs\n\n          -  LVEF <55% (MUGA scan or Echocardiogram),\n\n          -  Altered ophthalmic conditions confirmed by an ophthalmology specialist for patients\n             likely to be treated with AZD4547 orAZD8931 or Selumetinib :\n\n          -  Patients using non-substitutable drugs, that are known to prolong QT interval or\n             induce Torsades de Pointes, when they are supposed to be treated with vandetanib,\n             AZD5363 or AZD8931"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "650", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117167", 
            "org_study_id": "UC 0105-1305 / IFCT 1301", 
            "secondary_id": "2013-001653-27"
        }, 
        "intervention": [
            {
                "arm_group_label": "targeted agent", 
                "description": "Target : m-TOR", 
                "intervention_name": "AZD2014", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "targeted agent", 
                "description": "Target : FGFR", 
                "intervention_name": "AZD4547", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "targeted agent", 
                "description": "Target : AKT", 
                "intervention_name": "AZD5363", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "targeted agent", 
                "description": "target: HER2, EGFR", 
                "intervention_name": "AZD8931", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "targeted agent", 
                "description": "target : MEK", 
                "intervention_name": "Selumetinib", 
                "intervention_type": "Drug", 
                "other_name": "ARRY-142866"
            }, 
            {
                "arm_group_label": "targeted agent", 
                "description": "target : VEGF, EGFR", 
                "intervention_name": "Vandetanib", 
                "intervention_type": "Drug", 
                "other_name": "CAPRELSA"
            }, 
            {
                "arm_group_label": "Standard maintenance therapy", 
                "description": "Standard maintenance for squamous NSCLC", 
                "intervention_name": "Erlotinib", 
                "intervention_type": "Drug", 
                "other_name": "TARCEVA"
            }, 
            {
                "arm_group_label": "Standard maintenance therapy", 
                "description": "Standard maintenance for non squamous NSCLC", 
                "intervention_name": "Pemetrexed", 
                "intervention_type": "Drug", 
                "other_name": "ALIMTA"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 28, 2014", 
        "link": [
            {
                "url": "http://www.unicancer.fr"
            }, 
            {
                "url": "http://www.ifct.fr"
            }, 
            {
                "description": "SAFIR01 study results", 
                "url": "http://www.ncbi.nlm.nih.gov/pubmed/24508104"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "G\u00e9rard Zalcman"
                }, 
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France"
                    }, 
                    "name": "CHU Caen"
                }, 
                "investigator": {
                    "last_name": "G\u00e9rard Zalcman, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Denis Moro-Sibilot, Pr"
                }, 
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France"
                    }, 
                    "name": "CHU Grenoble"
                }, 
                "investigator": {
                    "last_name": "Denis Moro-Sibilot, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Fabrice Barlesi, Pr"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Nord"
                }, 
                "investigator": {
                    "last_name": "Fabrice Barl\u00e9si, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer", 
        "overall_contact": {
            "email": "s-verrier@unicancer.fr", 
            "last_name": "Sophie VERRIER, PhD", 
            "phone": "+ 33 1 71 93 63 64"
        }, 
        "overall_official": {
            "affiliation": "Gustave Roussy Villejuif", 
            "last_name": "Jean-Charles SORIA, Pr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate whether treatment with targeted agents guided by high throughput molecular analysis (CGH array, next generation sequencing) improves progression-free survival as compared to standard maintenance therapy in patients with metastatic NSCLC.", 
            "measure": "progression-free survival in the targeted drug arm compared to standard maintenance therapy arm", 
            "safety_issue": "No", 
            "time_frame": "from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated  treatment duration average: 4 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117167"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall survival in both arms", 
                "safety_issue": "No", 
                "time_frame": "from randomization to death (any cause), up to 16 months"
            }, 
            {
                "description": "tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria", 
                "measure": "overall disease response rates and changes in tumor size in both arms", 
                "safety_issue": "No", 
                "time_frame": "tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated  treatment duration average: 4 months)"
            }, 
            {
                "description": "tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria", 
                "measure": "disease response rate for each evaluated drug", 
                "safety_issue": "No", 
                "time_frame": "tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated  treatment duration average: 4 months)"
            }, 
            {
                "description": "Toxicities are graded according to the CTCAE V4", 
                "measure": "Number of patients presenting with acute or delayed toxicities to each drug", 
                "safety_issue": "Yes", 
                "time_frame": "toxicities will be assessed during the whole treatment period (4 months expected in average) followed by a 1-year post-treatment follow-up period, and reported during the visits scheduled by the study flow chart"
            }, 
            {
                "measure": "Progression free and overall survival measured for each evaluated drug", 
                "safety_issue": "No", 
                "time_frame": "from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated  treatment duration average: 4 months)"
            }
        ], 
        "source": "UNICANCER", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "IFCT", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Fondation ARC", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "AstraZeneca", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "UNICANCER", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}